ATG13

Across TCGA pan-cancer cohorts, ATG13 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATG13 data layer compared with 20 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATG13 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ATG13 expression acts as an unfavorable survival marker, although some lineages such as LSCC and HNSC show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where ATG13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	III,IV	0.272	0.727	.006	17	view →
LSCC	OS	Median	II,III,IV	0.882	0.593	.009	8	view →
HNSC	DFS	Tertile	III,IV	0.917	0.407	.040	4	view →
PDAC	DFS	Median	III,IV	0.363	0.656	.039	2	view →
CCRCC	DFS	Tertile	III,IV	0.222	0.981	.049	2	view →
GBM	OS	Tertile	All	0.287	0.626	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATG13–LUAD (OS)

Open the LUAD breakdown →